Inhibikase Therapeutics, Inc. (IKT)
Automate Your Wheel Strategy on IKT
With Tiblio's Option Bot, you can configure your own wheel strategy including IKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IKT
- Rev/Share 0.0
- Book/Share 0.9575
- PB 2.141
- Debt/Equity 0.0009
- CurrentRatio 11.0126
- ROIC -0.4476
- MktCap 152400075.0
- FreeCF/Share -0.2165
- PFCF -7.8619
- PE -5.0221
- Debt/Assets 0.0008
- DivYield 0
- ROE -0.7896
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IKT | H.C. Wainwright | Buy | Neutral | -- | -- | Feb. 12, 2025 |
News
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Inhibikase Announces Expansion of Senior Leadership Team
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (“PAH”) to its senior leadership team. Chris Cabell, M.D.
Read More
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025.
Read More
About Inhibikase Therapeutics, Inc. (IKT)
- IPO Date 2020-12-23
- Website https://www.inhibikase.com
- Industry Biotechnology
- CEO Mr. Mark T. Iwicki
- Employees 15